Abstract
ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have rapidly changed the treatment landscape, demonstrating dramatic clinical efficacy in various cancers. Areas covered In urothelial cancer (UC), several ICIs have been approved in platinum refractory disease and also as first-line therapy in patients that fulfill the criteria for cisplatin ineligibility. Atezolizumab is a monoclonal antibody that targets the immune checkpoint Programmed Cell Death Ligand-1 (PD-L1) and has been currently approved for advanced UC, non-small cell lung cancer, small cell lung cancer, and triple-negative breast cancer. Herein, we provide a summary of the mechanism of action, safety, and clinical efficacy of atezolizumab in UC. Expert opinion Atezolizumab is a drug with a favorable toxicity profile and will obtain more indications in the future in UC and other cancers. Treating physicians should be aware of treatment-related and immune-related adverse events associated with the drug.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
